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Introduction: Hemophagocytic lymphohistiocytosis is characterized by multisystem inflammation, resulting from
prolonged and intense activation of macrophages, histiocytes and CD8+ T-cells. Due to its variable presentation
and non-specific findings, timely diagnosis can be challenging. This condition has been associated with
malignancies, most commonly with lymphomas and leukemias of T-cell lineage. This case report represents the less
commonly associated B-cell lymphomas. We also highlight the difficulties in managing hemophagocytosis with an
evolving malignancy. This case report will add to the increasing literature on the diagnosis, complications and
management of this complex disorder.
Case presentation: A 15-year-old Caucasian girl, previously diagnosed with Crohn’s disease and treated with 6-
mercaptopurine, developed Epstein-Barr virus infection-driven hemophagocytic lymphohistiocytosis. The diagnosis
was challenging due to her critical illness and the lack of enough features to fulfill diagnostic criteria at presentation
(moderately elevated ferritin, normal coagulation profiles and normal triglycerides). While receiving therapy for
hemophagocytic lymphohistiocytosis, she developed bulky cervical lymphadenopathy and was diagnosed with
diffuse large B-cell lymphoma. Therapy for lymphoma was initiated and she tolerated the therapy well.
Conclusion: Hemophagocytic lymphohistiocytosis is a rare disorder, but potentially lethal if not diagnosed and
treated in a timely manner. Our case highlights the importance of considering this diagnosis in critically ill patients
who may not initially fulfill formal diagnostic criteria. In patients diagnosed with hemophagocytic
lymphohistiocytosis, occult malignancies should be aggressively ruled out as they can manifest prior to the
hemophagocytic lymphohistiocytosis diagnosis or appear during the treatment phase. An accurate diagnosis is also
important because management of Epstein-Barr virus-driven hemophagocytic lymphohistiocytosis and Epstein-Barr
virus-driven lymphoma differs due to the difference in pathophysiology and the involvement of different immune
cell lines.Introduction
Hemophagocytic lymphohistiocytosis (HLH) is charac-
terized by multisystem inflammation, resulting from pro-
longed and intense activation of macrophages, histiocytes
and CD8+ T-cells. Minimal clinicopathologic criteria for
the diagnosis of HLH, established by the Histiocyte* Correspondence: rodriguez.vilmarie@mayo.edu
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reproduction in any medium, provided the orSociety [1], include demonstration of a genetic alteration
consistent with HLH or demonstration of at least five of
the following eight criteria: fever, splenomegaly, cytopenia
(affecting two or more cell lines), hypertriglyceridemia,
hypofibrinogenemia, hemophagocytosis, low or absent
natural killer (NK) cell cytotoxicity, an increased ferritin
level and an increased level of soluble interleukin-2 recep-
tor (sCD25) [1].
Two forms of HLH are classically described; primary and
secondary. Primary or inherited HLH is an autosomal
recessive disorder. Rarely, it can be seen as an X-linkedd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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hibitor of apoptosis protein, formerly BIRC4) mutations
and X-linked lymphoproliferative disease. It usually mani-
fests during infancy, but rare cases have been described in
older children and adults [2]. The secondary or acquired
form is caused by a variety of diseases including viral, bac-
terial and protozoan infections, malignancies and macro-
phage activation syndrome associated with autoimmune








Hemoglobin (g/dL) 12 to 15.5 7.7 9.6
White blood cells (×109/L) 3.5 to 10.5 0.3 3.1
Absolute neutrophil count
(×109/L)
1.7 to 7.0 0 2.39
Platelets (×109/L) 150 to 450 17 99
Ferritin (mcg/L) 11 to 307 4,485 1,749Case presentation
A 15-year-old Caucasian girl with Crohn’s disease, who
was on immunosuppressive therapy with oral 6-
mercaptopurine, presented with fevers and sore throat, six
months after her diagnosis of inflammatory bowel disease.
On examination, she had bilateral tonsillar hypertrophy
with basilar exudate. Epstein-Barr virus (EBV) serologies
showed the presence of viral capsid antigen immuno-
globulin M, immunoglobulin G and positivity for EBV nu-
clear antigen suggesting reactivation of the infection
(Table 1). She went on to develop significant jaundice and
liver function tests revealed elevated transaminases and
direct hyperbilirubinemia (Table 2). An ultrasound of her
liver did not show any obstructive pathology. The patient
was hospitalized because of her persistent fevers along
with jaundice, with the admitting diagnosis of EBV-
induced cholestatic hepatitis. Serologies for hepatitis A, B
and C, cytomegalovirus and human immunodeficiency
virus (HIV) were negative. EBV copies continued to rise
throughout the course of her illness, from 1,500 to 20,000
copies/mL. She continued to be febrile and developed se-
vere respiratory distress and hypoxemia, requiring transfer
to the pediatric Intensive Care Unit.
A bone marrow biopsy and a diagnostic lumbar punc-
ture were performed. Her cerebrospinal fluid showed
evidence of pleocytosis. The bone marrow biopsy
showed pancytopenia and increased lymphohistiocytic
infiltrates with prominent hemophagocytosis (Figure 1).
The significant inflammatory response with high fevers
and pancytopenia was attributed to her being infected
with EBV. A decision was made to administer one dose
of rituximab and high dose immunoglobulins to control
the exaggerated immune response.Table 1 Epstein-Barr virus serologies during the course of
illness
Diagnosis of HLH At completion of therapy
EBV nuclear antigen Positive Negative
EBV viral capsid antigen
immunoglobulin G
Positive Negative
EBV viral capsid antigen
immunoglobulin M
Positive Negative
EBV: Epstein-Barr virus; HLH: hemophagocytic lymphohistiocytosis.There was laboratory evidence of cytopenia, with results
notable for falling neutrophil count, severe anemia and
thrombocytopenia (Table 2). There was moderate elevation
of ferritin and triglycerides. Her soluble CD25 (soluble
interleukin-2 receptor) level was elevated at 39,322U/mL.
(this information was not available at initial presentation).
There was complete absence of CD16 and CD56 positive
NK cells. NK cytotoxicity, porphyrin and granzyme testing
could not be done with the initial presentation due to the
absence of NK cells. Fibrinogen and coagulation studies
remained within normal limits. Our patient was diagnosed
with EBV-driven HLH as she fulfilled five of the eight
required criteria for diagnosis, and she was started on
chemotherapy with etoposide, dexamethasone and ciclos-
porin based on HLH 2004 protocol.
Testing was also done to rule out HIV and other immune
deficiencies. Genetic testing was carried out to rule out PRF
1, UNC13D, STX11 and STXBP2 mutations as well as sig-
naling lymphocytic activation molecule-associated protein
expression (SLAM) on cytotoxic lymphocytes.
Our patient had moderate cervical lymphadenopathy
(2cm), which was attributed to her EBV viremia at the time
of diagnosis of HLH. There was moderate splenomegaly on
a computed tomography scan of her abdomen but no other
significant lymphadenopathy was noted, hence the diagno-
sis of lymphoma was not strongly considered. No further
doses of rituximab were administered once HLH therapy
was started. Her chemotherapeutic regimen included dexa-
methasone, etoposide and ciclosporin. Our patient received
eight weeks of therapy on this protocol. She responded to
therapy and improved clinically.Fibrinogen (mg/dl) 200 to 430 309
Aspartate transaminase (U/L) 8 to 43 146 38
Alanine transaminase (U/L) 7 to 45 264 45
Total bilirubin (mg/dL) 0.1 to 1.0 6.5 0.7
Direct bilirubin (mg/dL) 0.0 to 0.3 4.4 0.4
Triglycerides (mg/dL) - 341 -
Epstein-Barr virus copies - 20,500 1,500





Figure 1 Bone marrow biopsy and aspirate showing hemophagocytosis and positive staining for CD68 marker for the presence of
macrophages.
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her cervical region two months after the initiation of
therapy, an excisional biopsy of the cervical mass was
performed (Figure 2). Pathology results were consistent
with EBV-positive diffuse large B-cell lymphoma. EBV
viremia at the time of diagnosis of lymphoma was
reported at 1,500 copies in the blood (Table 2). Immu-
nohistochemistry results were positive for CD20, CD19
and CD79a. A positron emission tomography scan
showed extensive involvement of her supraclavicular and
cervical lymph nodes as well as some involvement of her
liver (Figure 3). A bone marrow biopsy showed no evi-
dence of involvement of lymphoma or hemophagocyto-
sis. Treatment for lymphoma was given with six cycles
of rituximab, cyclophosphamide, doxorubicin, vincristine
and prednisone (R-CHOP) based on our institutional
standard of care for patients sixteen years of age and
older. Treatment related complications included pro-
longed fever and neutropenia. Restaging with positron
emission tomography at the end of her R-CHOP therapy
showed complete resolution. Our patient is now disease-
free after completion of therapy. She has been off immu-
nosuppressives for her Crohn’s disease since her recov-
ery from lymphoma, and has also been in remission for
over 24 months now.
Discussion
This case highlights the importance of making the diag-
nosis of HLH in a critically ill patient. The challenge
presented in our patient was the limited number of
HLH diagnostic criteria, with only a moderate elevation
of ferritin noted compared with other patients diagnosedwith HLH [4]. There was absence of a coagulopathy and
abnormal triglycerides. Hence, at her initial presentation,
she did not fulfill five of the eight criteria. Eventually she
fulfilled the required five of eight criteria, including per-
sistent fevers, cytopenia, splenomegaly, elevated CD25
and presence of hemophagocytes on a bone marrow bi-
opsy. She had elevated EBV serologies and polymerase
chain reaction copies.
Infection-associated HLH has been reported with EBV,
cytomegalovirus, hepatitis A, B and C, parvovirus, human
herpes virus 6 and 8, HIV, measles, mumps and rubella. In
addition, a variety of bacterial, fungal and protozoan infec-
tions have been described [5].
Patients with inflammatory bowel disease on immuno-
modulating drugs like azathioprine and 6-mercaptopurine
have been reported to develop HLH [6,7]. The diagnosis
of our patient’s Crohn’s disease was confirmed by biopsy
showing evidence of terminal ileitis. She was on immuno-
suppressive therapy for six months with 75mg of 6-
mercaptopurine prior to the diagnosis of HLH. Further
extensive evaluation for immune deficiencies did not re-
veal any associated primary immunodeficiency to be the
cause.
In our patient, there was no clear evidence of lymph-
oma at presentation, with an absence of significant
lymphadenopathy on clinical examination and imaging
(computed tomography of her chest, abdomen and
pelvis). Physical and imaging studies suggested the possi-
bility of reactive lymphadenopathy due to EBV viremia
and an excisional biopsy was not pursued at initial pres-
entation. It is possible that our patient might have pre-





Figure 2 Lymph node biopsy showing atypical diffuse large B-cell lymphoma cells positive for CD20, immunohistochemistry showing
negativity for CD3, and in situ hybridization using Epstein-Barr virus encoded probes showing diffuse positivity for the virus.
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kine storm secondary to EBV; however, our patient had
clear clinical and imaging evidence of lymphoma by the
time she completed the induction phase for her HLH.
Malignancy-associated HLH may develop before the
diagnosis of cancer or during the treatment phase. It is
mostly described in association with T-cell or NK cellFigure 3 Positron emission tomography scan at diagnosis of lymphomlymphomas or leukemias [8-10]. Hemophagocytosis and B-
cell lymphomas are described in the majority of Asian
patients and it is hypothesized that there may be genetic
and environmental factors pertinent to this population
which may be responsible for the transformation to B-cell
lymphoma [11]. Hence, it is recommended that, in children
with systemic HLH, a diagnosis of non-Hodgkin lymphomaa and at completion of therapy.
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the possible presence of a malignancy [12].
Defects in interleukin-2 inducible T-cell kinase gene
(ITK) are being noticed in females with EBV-induced
HLH, clinically resembling X-linked lymphoproliferative
disorder [13]. Testing for ITK did not show any abnor-
mality in the gene. Over 90% of patients with defects in
the XIAP gene develop HLH, associated with and with-
out EBV. These patients are also at risk for recurrent
HLH [14]. X-linked recessive inheritance of XIAP, is
rarely seen in females, unless there is skewed inactiva-
tion of the wild type X chromosome. We have not com-
pletely ruled out this rare possibility in our patient. HLH
is a disorder with an evolving spectrum of presentation.
So far, 70% of the patients with familial HLH have an
identified genetic mutation; 30% of North American
patients do not have identified mutations in any of the
four relevant genes [15]. As more genetic associations
are identified, we will learn more about genotype-
phenotype correlations in this disorder.
Our report highlights the spectrum of findings asso-
ciated with EBV infections, and the clinical overlap be-
tween EBV-driven HLH and EBV-driven lymphoma. The
initial presentation was that of secondary HLH related
to EBV infection, which was suspected due to persist-
ently rising EBV titers and the possibility of a weakened
T-cell system from the immunosuppressive therapy for
Crohn’s disease. Our patient may have been in the pre-
clinical stages of lymphoma triggered by EBV affecting
the B-lymphocytes, and this transformation was possibly
hastened by the presence of impaired T-cells and histio-
cytes. The clinical distinction between EBV-related HLH
and EBV-associated lymphoma is also important for
management purposes. Our patient responded clinically
to HLH therapy, but would have gone on to develop fur-
ther complications of lymphoma if this had not been
promptly recognized. After completion of the lymphoma
therapy, our patient has been in complete remission.
Due to a lack of evidence of a primary immune defi-
ciency and excellent response to therapy, bone marrow
transplantation was not considered. Vigilant follow-up
with imaging at scheduled intervals will be required for
a prolonged period of time.Conclusion
HLH is a rare disorder, but potentially lethal if not diag-
nosed and treated in a timely manner. Our case high-
lights the importance of considering this diagnosis in
critically ill patients who may not initially fulfill formal
diagnostic criteria. Potential complications of this dis-
order, including malignancy, should also be anticipated.
In patients diagnosed with HLH, occult malignancies
should be aggressively ruled out.Consent
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